The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol
Abstract
Rationale: Glucagon is a key hormone that regulates the adaptive metabolic responses to fasting. In addition to maintaining glucose homeostasis, glucagon participates in the regulation of cholesterol metabolism; however, the molecular pathways underlying this effect are incompletely understood. Objective: We sought to determine the role of hepatic Gcgr (glucagon receptor) signaling in plasma cholesterol regulation and identify its underlying molecular mechanisms. Methods and Results: We show that Gcgr signaling plays an essential role in LDL-C (low-density lipoprotein cholesterol) homeostasis through regulating the PCSK9 (proprotein convertase subtilisin/kexin type 9) levels. Silencing of hepatic Gcgr or inhibition of glucagon action increased hepatic and plasma PCSK9 and resulted in lower LDLR (LDL receptor) protein and increased plasma LDL-C. Conversely, treatment of wild-type (WT) mice with glucagon lowered LDL-C levels, whereas this response was abrogated in Pcsk9 −/− and Ldlr −/− mice. Our gain- and loss-of-function studies identified Epac2 (exchange protein activated by cAMP-2) and Rap1 (Ras-related protein-1) as the downstream mediators of glucagon’s action on PCSK9 homeostasis. Moreover, mechanistic studies revealed that glucagon affected the half-life of PCSK9 protein without changing the level of its mRNA, indicating that Gcgr signaling regulates PCSK9 degradation. Conclusions: These findings provide novel insights into the molecular interplay between hepatic glucagon signaling and lipid metabolism and describe a new posttranscriptional mechanism of PCSK9 regulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, an in-depth analysis of these DEGs revealed significant enrichment in pathways including the cAMP signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, insulin signaling pathway, insulin resistance, Glucagon signaling pathway and PPAR signaling pathway, which were closely implicated in lipid metabolism, as supported by previous studies”
From ABCC4 impairs the clearance of plasma LDL cholesterol through suppressing LDLR expression in the liver (2025) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, cAMP and its downstream signaling pathways are known to regulate PCSK9 homeostasis and LOX-1 expression45,46.”
From ABCC4 impairs the clearance of plasma LDL cholesterol through suppressing LDLR expression in the liver (2025) · cites this paper as [45]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Given previous reports linking glucagon signaling to PCSK9 regulation45,71”
From ABCC4 impairs the clearance of plasma LDL cholesterol through suppressing LDLR expression in the liver (2025) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“Several lines of evidence has conceived that EPAC2 plays significant roles in the liver45,71,96, endocrine glands and brain97–99.”
From ABCC4 impairs the clearance of plasma LDL cholesterol through suppressing LDLR expression in the liver (2025) · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381
Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover
Unger, R. H., & Cherrington, A. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60016 · Cited by 670
Selection and evaluation of clinically relevant AAV variants in a xenograft liver model
Lisowski, L., Dane, A. P., Chu, K., Zhang, Y., Cunningham, S. C., Wilson, E. M., Nygaard, S., Grompe, M., Alexander, I. E., & Kay, M. A. (2014) · Nature · doi:10.1038/nature12875 · Cited by 450
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis
Wang, X., Zheng, Z., Caviglia, J. M., Corey, K. E., Herfel, T. M., Cai, B., Masia, R., Chung, R. T., Lefkowitch, J. H., Schwabe, R. F., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.016 · Cited by 413
PARTICIPATION OF LYSOSOMES IN CELLULAR AUTOPHAGY INDUCED IN RAT LIVER BY GLUCAGON
Deter, R. L., Baudhuin, P., & de Duve, C. (1967) · The Journal of Cell Biology · doi:10.1083/jcb.35.2.c11 · Cited by 357
Physiologic action of glucagon on liver glucose metabolism
Ramnanan, C. J., Edgerton, D. S., Kraft, G., & Cherrington, A. D. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01454.x · Cited by 293
The Glucagon Receptor Is Required for the Adaptive Metabolic Response to Fasting
Longuet, C., Sinclair, E. M., Maida, A., Baggio, L. L., Maziarz, M., Charron, M. J., & Drucker, D. J. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.09.008 · Cited by 272
Finan, B., Clemmensen, C., Zhu, Z., Stemmer, K., Gauthier, K., Müller, L., De Angelis, M., Moreth, K., Neff, F., Perez-Tilve, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.014 · Cited by 191
Research works printed but not linked: 64
- 10.1161/CIR.0000000000000366 · DOI
- 10.1016/S0140-6736(12)61190-8 · DOI · Paper page
- 10.1038/ng1161 · DOI · Paper page
- 10.1016/j.tibs.2006.12.008 · DOI · Paper page
- 10.1161/CIRCRESAHA.118.311227 · DOI · Paper page
- 10.1097/MED.0000000000000137 · DOI · Paper page
- 10.1073/pnas.0335507100 · DOI · Paper page
- 10.1007/s00125-016-3965-9 · DOI
- 10.1073/pnas.0237106100 · DOI · Paper page
- 10.1016/0005-2760(89)90042-8 · DOI
- 10.1210/jcem-64-1-106 · DOI · Paper page
- 10.1111/j.1463-1326.2011.01449.x · DOI · Paper page
- 10.1080/13543784.2017.1395020 · DOI
- 10.1111/dom.12672 · DOI · Paper page
- Engel, SS, Reitman, ML, Xu, L, Andryuk, PJ, Davies, MJ, Kaufman, KD, Goldstein, BJ. Glycemic and lipid effects of the short-acting glucagon receptor antagonist mk-3577 in patients with type 2 diabetes. Diabetes. 2012;61:A266–A266.
- 10.1111/dom.12958 · DOI · Paper page
- 10.1194/jlr.P009860 · DOI
- 10.1210/en.2008-1281 · DOI
- 10.1074/jbc.M412595200 · DOI
- 10.4161/sgtp.2.2.15735 · DOI
- 10.2217/clp.12.70 · DOI
- 10.1016/j.molmet.2014.11.005 · DOI
- 10.1016/j.molmet.2017.06.012 · DOI
- 10.1194/jlr.M035592 · DOI
- 10.1074/jbc.M109.037085 · DOI · Paper page
- 10.1002/hep.22354 · DOI · Paper page
- 10.1194/jlr.M003566 · DOI
- 10.1530/JME-15-0316 · DOI
- 10.1146/annurev.pharmtox.010909.105714 · DOI
- 10.1152/ajpgi.00517.2003 · DOI
- 10.1172/JCI107096 · DOI
- 10.1111/j.1527-3466.2006.00261.x · DOI
- 10.1002/cbic.200800216 · DOI
- 10.1161/CIRCRESAHA.115.306529 · DOI
- 10.1016/j.lfs.2011.01.023 · DOI
- 10.1161/CIRCULATIONAHA.113.001592 · DOI · Paper page
- 10.1194/jlr.M028563 · DOI · Paper page
- 10.1097/MOL.0000000000000239 · DOI
- 10.1074/jbc.M109.052407 · DOI
- 10.1074/jbc.M113.481473 · DOI
- 10.1016/j.cmet.2012.03.002 · DOI
- 10.1016/j.cmet.2013.10.011 · DOI
- 10.1111/dom.13202 · DOI
- 10.1016/0026-0495(67)90060-1 · DOI
- Caren, R, Corbo, L. Glucagon and cholesterol metabolism. Metabolism. 1960;9:938–945.
- Amatuzio, DS, Grande, F, Wada, S. Effect of glucagon on the serum lipids in essential hyperlipemia and in hypercholesterolemia. Metabolism. 1962;11:1240–1249.
- Paloyan, E, Harper, PV, Jr. Glucagon as a regulating factor of plasma lipids. Metabolism. 1961;10:315–323.
- 10.1038/nm.3761 · DOI · Paper page
- 10.1172/JCI116522 · DOI
- 10.1371/journal.pone.0186586 · DOI
- 10.1006/geno.2001.6641 · DOI · Paper page
- 10.1038/ijo.2016.208 · DOI
- 10.2337/db14-0576 · DOI
- 10.1096/fj.13-230433 · DOI
- 10.1126/science.1172256 · DOI
- 10.1161/ATVBAHA.115.305688 · DOI
- 10.1074/jbc.M113.453373 · DOI · Paper page
- 10.1042/bj1860071 · DOI
- 10.1242/jcs.107.6.1661 · DOI
- 10.1016/j.ceb.2017.01.008 · DOI · Paper page
- 10.1016/j.semcdb.2014.04.011 · DOI
- 10.1007/s10059-012-0097-z · DOI
- 10.1007/s00018-016-2449-x · DOI
- 10.1242/jcs.191858 · DOI
Cited by
Sorted by citations
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
PCSK9 in metabolism and diseases
Ajoolabady, A., Pratico, D., Mazidi, M., Davies, I. G., Lip, G. Y. H., Seidah, N., Libby, P., Kroemer, G., & Ren, J. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156064 · Cited by 49
Wang, M.-Y., Zhang, Z., Zhao, S., Onodera, T., Sun, X.-N., Zhu, Q., Li, C., Li, N., Chen, S., Paredes, M., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.024 · Cited by 52
Zheng, X., Yuan, W., Li, L., Ma, H., Zhu, M., Li, X., & Feng, X. (2025) · European Journal of Medical Research · doi:10.1186/s40001-025-02937-1 · Cited by 9
Chen, J., Huang, H., Chen, C., Xia, G., Huang, H., Xiong, Y., Luo, P., Chen, Y., Li, J., Wen, L., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08818-x · Cited by 1
Metadata
- Authors
- Spolitu, S., Okamoto, H., Dai, W., Zadroga, J. A., Wittchen, E. S., Gromada, J., & Ozcan, L.
- Venue
- Circulation Research
- Published
- 2019-01-04
- Volume
- 124
- Issue
- 1
- Pages
- 38-51
- ISSN
- 0009-7330
- 1524-4571
- PMC
- PMC6457439
- Cited by
- 64
- References
- 13
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
